meglumine antimoniate has been researched along with pentoxifylline in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Báfica, A; Barral, A; Freitas, LA; Nascimento, EG; Oliveira, F | 1 |
| Nilforoushzadeh, MA; Sadeghian, G | 1 |
| de Moura, FJ; de Souza Furtado, R; Leal, PP; Muniz-Junqueira, MI; Veiga, JP | 1 |
| Elias, VM; Osorio-Arango, K; Pinart, M; Pinzón-Flórez, CE; Reveiz, L; Romero, GA; Rueda, JR; Silveira Maia-Elkhoury, AN; Tweed, JA | 1 |
| Brustolin, AÁ; de Castro, KR; Mota, CA; Pelloso, SM; Ramos-Milaré, ÁCFH; Silveira, TGV | 1 |
1 review(s) available for meglumine antimoniate and pentoxifylline
| Article | Year |
|---|---|
Interventions for American cutaneous and mucocutaneous leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Azithromycin; BCG Vaccine; Female; Humans; Hyperthermia, Induced; Immunocompetence; Injections, Intramuscular; Injections, Intravenous; Interferon-gamma; Leishmaniasis Vaccines; Leishmaniasis, Cutaneous; Leishmaniasis, Mucocutaneous; Male; Meglumine Antimoniate; Pentoxifylline; Phosphorylcholine; Randomized Controlled Trials as Topic | 2020 |
1 trial(s) available for meglumine antimoniate and pentoxifylline
| Article | Year |
|---|---|
Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
Topics: Adolescent; Adult; Antiprotozoal Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hematologic Agents; Humans; Iran; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pentoxifylline; Treatment Outcome | 2006 |
3 other study(ies) available for meglumine antimoniate and pentoxifylline
| Article | Year |
|---|---|
American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.
Topics: Administration, Oral; Antiprotozoal Agents; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pentoxifylline; Tumor Necrosis Factor-alpha | 2003 |
Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride.
Topics: Animals; Antimony; Antiprotozoal Agents; Chlorides; Dose-Response Relationship, Drug; Kidney Diseases; Kidney Function Tests; Leishmaniasis; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Pentoxifylline; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2008 |
Successful combined therapy with Glucantime™ and pentoxifylline for the nasal mucosal lesion recently developed in a leishmaniasis patient having untreated cutaneous lesion for seven decades.
Topics: Aged; Brazil; Drug Therapy, Combination; Female; Humans; Leishmania; Leishmaniasis, Mucocutaneous; Meglumine Antimoniate; Pentoxifylline; Trypanocidal Agents | 2021 |